By the num­bers: 2-year tal­ly of Cel­gene's biotech part­ner­ship deals tops $3B in cash

Bob Hug­in and his busy deal­mak­ing wiz George Golumbes­ki have po­si­tioned Cel­gene as an in­dus­try-lead­ing wheel­er and deal­er.

$1 bil­lion to part­ner with Juno on CAR-T? OK. $200 mil­lion in cash to rewrite a pact with Agios? They’ll take that. An­oth­er $450 mil­lion to part­ner with As­traZeneca on its check­point? No prob­le­mo. As big­ger com­pa­nies fret­ted over the val­u­a­tions they were see­ing in the biotech boom, Cel­gene’s ex­ec­u­tive team were struck by the op­por­tu­ni­ties. “If we see them, we’re go­ing to go af­ter them at the right time,” Cel­gene CEO Bob Hug­in told me last sum­mer, af­ter grab­bing Re­cep­tos for its im­munol­o­gy pipeline for $7.2 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.